Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Eledon Pharmaceuticals (Nasdaq: ELDN) has announced its participation in the Guggenheim Securities Inaugural Healthcare Innovation Conference. CEO David-Alexandre C. Gros, M.D., will engage in a fireside chat on Wednesday, November 13, 2024, at 1:30 p.m. ET (10:30 a.m. PT). The presentation will be available via webcast, with advance registration required. A replay of the session will be accessible on the company's investor relations website following the live event.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha annunciato la sua partecipazione alla Conferenza Inaugurale sulle Innovazioni Sanitarie di Guggenheim Securities. Il CEO David-Alexandre C. Gros, M.D., parteciperà a una chat informale mercoledì 13 novembre 2024, alle 13:30 ET (10:30 PT). La presentazione sarà disponibile via webcast, con registrazione anticipata richiesta. Una registrazione della sessione sarà accessibile sul sito web delle relazioni con gli investitori dell'azienda dopo l'evento dal vivo.
Eledon Pharmaceuticals (Nasdaq: ELDN) ha anunciado su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim Securities. El CEO David-Alexandre C. Gros, M.D., participará en una charla informal el miércoles 13 de noviembre de 2024, a la 1:30 p.m. ET (10:30 a.m. PT). La presentación estará disponible a través de un webcast, requiriendo registro previo. Una repetición de la sesión estará accesible en el sitio web de relaciones con inversores de la compañía después del evento en vivo.
엘레돈 제약 (Nasdaq: ELDN)은 구겐하임 증권 주관의 첫 번째 의료 혁신 컨퍼런스에 참가한다고 발표했습니다. CEO인 David-Alexandre C. Gros, M.D.는 2024년 11월 13일 수요일 오후 1:30 ET (오전 10:30 PT)에 이야기를 나누는 시간을 가질 예정입니다. 발표는 웹캐스트를 통해 제공되며 사전 등록이 필요합니다. 라이브 이벤트 이후 회사의 투자자 관계 웹사이트에서 세션의 재생을 이용할 수 있습니다.
Eledon Pharmaceuticals (Nasdaq: ELDN) a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim Securities. Le PDG David-Alexandre C. Gros, M.D., participera à une discussion informelle le mercredi 13 novembre 2024, à 13h30 ET (10h30 PT). La présentation sera disponible par webcast, avec une inscription préalable requise. Un enregistrement de la session sera accessible sur le site Web des relations investisseurs de la société après l'événement en direct.
Eledon Pharmaceuticals (Nasdaq: ELDN) hat seine Teilnahme an der Erstveranstaltung des Guggenheim Securities Healthcare Innovation Conferences angekündigt. CEO David-Alexandre C. Gros, M.D., wird am Mittwoch, den 13. November 2024, um 13:30 Uhr ET (10:30 Uhr PT) an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Webcast verfügbar sein, wobei eine vorherige Registrierung erforderlich ist. Eine Wiederholung der Sitzung wird nach der Live-Veranstaltung auf der Website der Investor Relations des Unternehmens zugänglich sein.
- None.
- None.
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim Securities Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 1:30 p.m. ET (10:30 a.m. PT).
To register in advance for the presentation webcast, sign up here.
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/news-and-events/events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com
Source: Eledon Pharmaceuticals
FAQ
When is Eledon Pharmaceuticals (ELDN) presenting at the Guggenheim Healthcare Conference?
How can I watch Eledon's (ELDN) presentation at the Guggenheim Healthcare Conference?
What type of presentation will Eledon (ELDN) give at the Guggenheim Healthcare Conference?
Where can I find the replay of Eledon's (ELDN) Guggenheim Conference presentation?
